ClearPoint Neuro Aktie News

ClearPoint's stock surged after uniQure announced strong Huntington's data, highlighting the value of its drug delivery platform. CLPT's technology has been validated by the AMT-130 data, positioning the company for improved deal economics in future partnerships. Beyond Huntington's, CLPT's pipeline includes promising programs in Parkinson's and epilepsy.

New Product Category Will Enable Added Flexibility to Support Commercial Launches of Cell and Gene Therapy SOLANA BEACH, CALIFORNIA / ACCESS Newswire / October 1, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today formally announced the development and demonstration of th...

ClearPoint Neuro surged over 100% following positive Huntington's Disease data from partner uniQure, highlighting its drug delivery device's role in AMT-130 trials. CLPT's SmartFlow cannula is already FDA-labeled with Kebilidi, and AMT-130's larger market could make it a meaningful revenue driver if approved. Financially, CLPT expects margin expansion and cash flow breakeven by 2027, with a sol...

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / September 25, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that Dr. Paul Larson will be joining the company as Chief Medical Officer starting in January 2026. Dr. Larson has a long history of working with ClearP...

ClearPoint Neuro’s Expanded FDA Clearance: A Potential Catalyst for Growth

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / September 4, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that the ClearPoint Prism® Neuro Laser Therapy System ("ClearPoint Prism") received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to ...

ClearPoint Neuro's Q2 results were solid; although real upside is likely to be more apparent from 2026 onward. Key catalysts include the launch of GLP services and partner program commercialization, particularly uniQure's Huntington's therapy. Positive partner data and strong system placements could drive ClearPoint's stock higher in 2025.

ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Joseph Michael Burnett - President, CEO & Director Danilo D'Alessandro - Chief Financial Officer Conference Call Participants Frank James Takkinen - Lake Street Capital Markets, LLC, Research Division Anderson Schock - B. Riley Securities, Inc., Research Division Operator Greet...